Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head: which drug works better for psoriatic arthritis in the real world?

NCT ID NCT07386717

Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 70 people with psoriatic arthritis to compare two drug types: upadacitinib and IL-17 inhibitors. Researchers tracked joint and skin symptoms over 24 weeks in routine care. The goal is to see which works better in real life, helping doctors personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib and interleukin-17 inhibitors
What this could lead to
If this study shows one drug works better in real life, it could help doctors choose the best treatment for each person with psoriatic arthritis.
What could go wrong
This is a small, completed observational study, not a large trial. Results may not apply to everyone, and the 24-week follow-up is too short to see long-term effects or rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Diagnosis of psoriatic arthritis according to established classification criteria

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of psoriatic arthritis according to established classification criteria * Treatment with upadacitinib or an interleukin-17 inhibitor at baseline * Availability of baseline and follow-up clinical data over 24 weeks Exclusion Criteria: * Diagnosis of other inflammatory arthritides * History of malignancy or severe uncontrolled infection * Incomplete clinical data preventing outcome assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interleukin-17 inhibitors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interleukin-17 inhibitors Psoriatic arthritis Upadacitinib

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.